Pressurl: https://news.google.com/rss/articles/CBMi1gJBVV95cUxOejlzdkstc1dtUW9qYlowemxsWEpScXFib3VQeGtUaWw4TF9aa2R2enNTTG5oQmJuWm1lSXVIQzAydldXVGNzbEdHcVpBa0tYMU9EZXRLWldab3JOYXBlUEV0NzBKUmQyeXRFNExTOGJ6MHdaU3cwZUVjRjMwQllQNmR4Vjlia0U4eDB1cUg5Q2xFUHVzcHRCOFlCYWNtaVY2SjBQelYzTEVuRGNlXzhENkdjekZmbTA3bC1OZmdiVm50bWhsbFRPZWo2SUtlWm1Cdl9LUHdmQ1cxSGRtbUNkYmhwcWJIQlpRVHhXaHdhWElKM2o5alFIMndFaHNaODUxQ3F5b1E2ODVVdVRHdmRROV9PdElKUzljVDc3aktsckVQRzV0NnZpdTJWMWc1QjE0UU1ETUtfbWU4MzAtUmZXT0Y0WHVVNGZGbFdDeWl6OVZBVWpSVlE?oc=5 · headline: Epicrispr Reports Positive Six-Month Data at The World Muscle Society Meeting Demonstrating Increased Lean Muscle Volume and Muscle Strength in FSHD Patients Treated with EPI-321 · publication: Business Wiregoogle_news · 10/15/2026
Pressurl: https://news.google.com/rss/articles/CBMikwJBVV95cUxPeVp3bW1mNUtWVUpzLUlNWm5TMjROQzZFWlRKdXBuWEowdks3YWF3SjlmeEhuSmZocTFMZ2RnTy1YNjlxUFo4ajBuYjlHandsUWpMNTRBb3V3RUNUTUxMak9JdUR3cXl6Mzd3dTJYOThnUy0zWm1VZ1NyMUNlank2dmhDTHJiNWowXy1MVUQyRTIwN3U4bWhua2pMMVZqWEhULWNEWkpaQ3BnLXRHVzkxM3d2d2hiZDd2a1QzakFNNTJud0loWjVrU3gxQ24wWXBDRm5pQVA0NGE4RTB3bm45Smcyc0VEV2JLa2l6WDFKR0xoQmY1UXlvVTBnV2luMVpFaVFkeWh5dGs1THVESEtOZUZ5TQ?oc=5 · headline: Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following Treatment with EPI-321 · publication: Business Wiregoogle_news · 10/1/2026
url: https://news.google.com/rss/articles/CBMi8gFBVV95cUxQUDVFWXJNVVdfSWhEbUc1QXRMWTZZcnZ6NmdqTzZBTnMzUEhzb21kb0FuQ0FiaVp1Yk9YUkZZbVJ6bzI0NXhabkhxcXREWjFwMWpPSEFHOUU0eEtmaTFtS25lLWZ5b3lPbmstYmswVDRDWk5YZ0N3aTVmLUZIWi1KT1RxOEZ1bHl5bG9xSFZYamU3RER6ek1Ib0pKWkhOSHRzMHp2dHpHcmxZdnBPTFdlaVRYN2E2UU9QeFdVbkdSWm9aZ0xoRldZR1VPc1FhSW0wWW1SMGowcFljS1ptVnFGMC1XNEpkOWFkek9YUHFlVGI0dw?oc=5 · headline: Epicrispr Completes Enrollment and Dose Escalation in First-in-Human EPI-321 Trial for FSHD · publication: FinancialContent
google_news · 10/1/2026
Pressurl: https://news.google.com/rss/articles/CBMipwFBVV95cUxNb2tjQ1JkR2o2czdlTGtQVkJqR1plUzdpTEp4V21QbmJ3M0NTV3BLZ3NHbzM1X0pIQi1haWxab1pHS3hzLVk4UXZKS1dYUXRzVS1BYk54aG0yME1lbWhuMmRpUEJ3c2tINjU1YzNMTUV4aDgzd0FreHJEYW85VzBkSTlySldlekZjbG9MVGdISzBLcWt1S2N4aXpZLUMxTVU5dmhpdUtBdw?oc=5 · headline: Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD · publication: Yahoo Financegoogle_news · 10/1/2026
open_rolesroles: 2career_page · 9/27/2026
Pressurl: https://news.google.com/rss/articles/CBMioAFBVV95cUxOdFRsdU5NYUN1SXI2bUVwdDlZYWZGbTc3RGx4NVcxTUgwQU55Y1hhcWcwX0M0VTdTRm1ObHRMYzd1RnBPbXN0N2dQZVllUDlGU211RjlFMjg4ZmdoNUJETjZIVUhXRmN1TG1TdFBMN0hscDdHV2pmSUJfUDYydUYzc0YtRVA5Y0ZQQnZIbjNYSlgtOXdjNWxwZ2Fwd1VfTGpF?oc=5 · headline: Epigenetic Editors Make Their Marks in the Clinic · publication: Genetic Engineering and Biotechnology Newsgoogle_news · 9/1/2026
Pressurl: https://news.google.com/rss/articles/CBMiqwFBVV95cUxObHdPdEJiX2s3dWszZGRvWjEybG52LWxzWWQ1NXFPY0YxYzk5aG1fQkpQNUFXSGJuNms5bjlwZ1p3QnJCMi1oRWl1UTBqUW9sLWw5U3R4MzZZTlBiNWhMdE9OLWJtR2VSR0k1cHliN3BHTDZHd0wxZWZyV0pxN2hfVHhiVTBydjdMRGlRaG44Q0xoN2YxVDJYdHZ0RExBb2FWdU5hWXhid1psQTg?oc=5 · headline: Companies join forces to speed production of 1-time treatment for FSHD · publication: Muscular Dystrophy Newsgoogle_news · 9/1/2026
Pressurl: https://news.google.com/rss/articles/CBMirwFBVV95cUxOS0xPNW0wQnQzWDdQd0dZSUhxamxnVXF0MV9RSG9DbV9wTmt0Q3VEX1ozQ3VqXzl4NENqQk5fSUlBUFQtUlhsS25lZkxHM2FRUlRmbVlLelVadEtYeE1LWWhuSVdkSkFxYUlnSjFnOGN1dktWMEd0MUpaa3RLdWtKTndiM1hfbWdBT00wZV8wVTVzVlcyclduWk9KLWVUMVVEY210R3E4SWhFenpVUHlJ?oc=5 · headline: Next-generation CRISPR company raises $68 million, zeroes in on first clinical trial · publication: The Business Journalsgoogle_news · 9/1/2026